On the evening of August 27, the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards for China and Best Practices were grandly announced at the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards Ceremony and VIP Reception.
Based on the research and analysis of China's cell therapy market in recent years, as well as the study and evaluation of related companies in the industry, Frost & Sullivan has awarded the 'Frost & Sullivan China Cell Therapy Leadership Award' to Fosun Kailu (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as 'Fosun Kailu'). The award was presented on behalf of Fosun Kailu (Shanghai) Biotechnology Co., Ltd. by Sae-Jun Park, Head of Frost & Sullivan Korea and Member of the Frost & Sullivan East Asia Management Committee, Rhenu Bhuller, a strategic advisor to Frost & Sullivan Life Sciences and Digital Health and an expert advisor to the Global Expert Advisory Group of Frost & Sullivan.
Fosun Karry (Shanghai) Biotechnology Co., Ltd.
"China Cell Therapy Leadership Award"
Sae-Jun Park, Head of Frost & Sullivan Korea and Member of the Management Committee for East Asia at Frost & Sullivan, and Rhenu Bhuller, Strategic Advisor to Life Sciences and Digital Health at Frost & Sullivan and an expert advisor to the Global Expert Advisory Group at Frost & Sullivan, presented awards to representatives of Fosun Pharma (Shanghai) Biotechnology Co., Ltd.
Fosun Kaili is a technological pioneer and industrialization benchmark in the field of CAR-T cell therapy in China.
Fosun Karry (Shanghai) Biotechnology Co., Ltd. was established in 2017 and is headquartered in Zhangjiang, Shanghai. It is a leading domestic biopharmaceutical company focusing on the research, development, production, and commercialization of CAR-T cell therapy products. Relying on Fosun Pharma's global industrial platform, the company introduced Yescarta from Kite Pharma in the United States and localized its production.®In June 2021, it was approved as China's first CAR-T product - YikeDa®(Acelyximab Injection), with the addition of a second-line indication in June 2023, officially marks the beginning of the first year of CAR-T therapy in China. Currently, Yike Da®It has covered more than 190 high-standard treatment centers in 29 provinces across the country, having treated over 1,000 patients with large B-cell lymphoma.
With the mission of 'Focusing on Cure, Lighting Up Lives', we aim to make cell therapy accessible to patients worldwide.
Fosun Karry has deep cooperation with top centers such as the Chinese Academy of Medical Sciences Blood Disease Hospital and Ruijin Hospital, continuously promoting CAR-T clinical evidence-based research and real-world studies; in March 2025, Yikaida®The company has made its first export to Hong Kong, taking the lead in achieving the 'going global' of domestic CAR-T products. The company is simultaneously building a dual reporting path for China and the US, deeply cultivating markets in the Middle East and Southeast Asia, and constructing an international paradigm of 'global regulation - patient accessibility - diversified payment', striving to become a benchmark for Chinese innovation benefiting the world.
Driven by technology, value, and cognition, we build a sustainable commercial ecosystem.
Fosun Karry has built a CAR-T industrialization base of over 10,000 square meters and a cell therapy R&D center of over 2,000 square meters in Zhangjiang, Shanghai. It has achieved full-process automation, digitization, and lean management for more than 300 processes, personalized customization, significantly reducing production costs. It has also taken the lead in launching China's first 'efficacy-based payment' plan for lymphoma, which has been included in the People's Insurance Plan for 110+ cities and more than 80 commercial health insurance policies, forming a 'technology-payment-service' closed loop and continuously improving patient accessibility and market penetration.
About the Frost & Sullivan China Leadership Award
The Frost & Sullivan China Leadership Award recognizes outstanding performance and achievements in technology innovation, market potential, customer service, brand, and other aspects by enterprises. The Frost & Sullivan team, through in-depth interviews, industry analysis, secondary research, and other methods, nominated a competitive group of excellent companies to an independent judging panel. An independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and renowned listed entrepreneurs conducted a rigorous review of the companies nominated by the Frost & Sullivan team and decided to award the 'China Cell Therapy Leadership Award' to Fosun Kaili (Shanghai) Biotechnology Co., Ltd.
